Abstract: A composition for targeting low-density lipoprotein receptor-related protein 6 (LRP6)-overexpressed cells. The composition includes a peptide including at least one of SEQ ID NO: 1 and SEQ ID NO: 3.
Type:
Grant
Filed:
February 15, 2021
Date of Patent:
February 7, 2023
Assignees:
PASTEUR INSTITUTE OF IRAN, ELHAM RISMANI, LADAN TEIMOORITOOLABI
Inventors:
Elham Rismani, Ladan TeimooriToolabi, Morteza Karimipoor, Seyed Shahriar Arab
Abstract: The various embodiments herein provide a cell growth inhibitor derived from p16INK4a gene comprising a C-terminal segment of the p16INK4a gene, two ankyrin repeats i.e. ankyrin III and ankyrin IV of the p16INK4a gene, two loops i.e. loop 2 and loop 3 of the p16INK4a gene and residues along with the loop 2 consisting Phe90, Glu88, Gly89, Asp92 and Asp84 residues. The cell growth inhibitor is a truncated form of the p16INK4a gene and encompasses 66-156 amino acids of a full length p16INK4a gene. The cell growth inhibitor has 42% growth inhibition at 24 hrs. The embodiments herein also provide a method of synthesizing the cell growth inhibitor using a polymer chain reaction method.
Type:
Application
Filed:
September 20, 2011
Publication date:
March 21, 2013
Applicants:
Mohammad Hossein Ghahremani, PASTEUR INSTITUTE OF IRAN
Inventors:
Najmeh Fahham, Soroush Sardari, Mohammad Hossein Ghahremani
Abstract: The various embodiments herein provide a chimeric truncated and mutant variant of a tissue plasminogen activator (t-pa) and a method for preparing the same. According to an embodiment herein, the mutant variant comprises a signal sequence domain, followed by a chimeric tetrapeptide, followed by a tripeptide, followed by a kringle 2 domain, followed by a serine protease domain and a substituted amino acids at position 128-131. The substituted amino acids are AAAA (SEQ ID NO: 3) amino acids. The chimeric tetrapeptide is Gly-His-Arg-Pro (SEQ ID NO: 1). The chimeric tetrapeptide is at a position of 36 to 39 amino acid of the mutant variant. The tripeptide is Ser-Tyr-Glu. According to an embodiment herein, a chimeric truncated and mutant variant of a tissue plasminogen activator comprises a native t-pa deleted with Finger domain, a Growth Factor domain and a Kringle 1 domain, a chimeric tetrapeptide and a substituted amino acids at a position of 128-131.
Type:
Application
Filed:
July 27, 2011
Publication date:
March 8, 2012
Applicants:
PASTEUR INSTITUTE OF IRAN (IPI), No. 69
Abstract: The various embodiments herein provide a gold coated SPIONs with jagged surface. The gold coated SPIONs have a core and a shell. The core is a SPION molecule and the shell is a jagged gold layer. A non-uniform polymeric gap exists between the core and the shell. The embodiments also provide a method of producing the jagged gold coated SPIONs by mixing a colloidal dispersion of SPIONs with pH sensitive polymers. Adding a gold salt to the above mixture and reducing the gold salt to form jagged gold coated SPIONs.
Type:
Application
Filed:
April 30, 2011
Publication date:
August 25, 2011
Applicants:
PASTEUR INSTITUTE OF IRAN
Inventors:
Morteza Mahmoudi, Mohammad Ali Shokrgozar